last
decad
seen
rapid
advanc
diagnost
tool
novel
therapi
result
basic
research
fi
eld
divers
genom
drug
discoveri
inform
scienc
imag
nanotechnolog
mankoff
et
al
reec
area
advanc
knowledg
chang
practic
modern
medicin
howev
uptak
health
care
set
often
slow
haphazard
graham
et
al
kerner
clear
new
knowledg
clever
technolog
enough
improv
patient
care
basic
discoveri
must
link
insight
surround
develop
deliveri
deploy
applic
new
inform
techniqu
health
care
translat
success
occur
studi
translat
knowledg
health
care
translat
medicin
character
mani
way
one
defi
nition
effort
fi
nd
cure
affect
individu
complement
pursuit
understand
human
diseas
complex
mankoff
et
al
within
ideal
framework
advanc
basic
research
properli
test
clinic
set
knowledg
gain
fed
back
basic
research
effi
cientli
translat
new
therapeut
strategi
treat
cure
prevent
diseas
marincola
sonntag
howev
gap
translat
provis
new
knowledg
health
care
set
socal
translat
gap
occur
advers
impact
qualiti
medic
care
decreas
patient
safeti
escal
cost
exampl
import
topic
translat
medicin
estim
patient
receiv
medic
care
accord
best
scientifi
c
evid
fact
report
medic
care
current
provid
either
unnecessari
potenti
harm
graham
et
al
effort
close
translat
gap
focus
larg
part
perceiv
obstacl
challeng
translat
basic
research
viabl
diagnost
therapeut
strategi
includ
commun
educ
research
divers
fi
eld
institut
support
translat
research
activ
regulatori
hurdl
high
cost
develop
diagnost
novel
therapeut
need
bioinformat
complex
data
handl
capabl
adapt
new
technolog
highthroughput
autom
intellectu
properti
licens
protect
willing
move
away
standard
therapi
embrac
new
paradigm
diagnost
therapeut
strategi
horig
pullman
horig
et
al
hume
marincola
reec
tsongali
need
recogn
key
role
technolog
innov
close
translat
gap
medicin
compar
increment
improv
current
practic
howev
signifi
cant
health
gain
occur
fi
deliti
medic
advanc
deliv
optim
two
process
sometim
seen
compet
woolf
johnson
actual
repres
two
factor
necessari
medic
progress
may
area
clearli
demonstr
translat
diagnost
fi
eld
driven
innov
ratner
implement
genom
innov
diagnost
person
medicin
requir
translat
vast
array
technolog
therapeut
strategi
basic
scienc
clinic
applic
deliveri
diagnost
patient
requir
physician
patient
educ
well
evidencebas
demonstr
effi
caci
healthcar
uptak
payment
regulatori
approv
challeng
address
year
ago
academ
medic
center
primari
mechan
foster
translat
research
facilit
collabor
research
clinician
puderbaugh
multidisciplinari
educ
program
fund
primarili
privat
institut
dori
duke
charit
foundat
mankoff
et
al
unit
state
nation
institut
health
nih
food
drug
administr
fda
began
initi
identifi
fi
nanc
develop
translat
research
program
nih
roadmap
medic
research
aim
identifi
support
research
beyond
scope
singl
nih
compon
nih
roadmap
initi
sought
improv
develop
avail
modern
scientifi
c
tool
inform
resourc
foster
novel
method
research
collabor
enhanc
nation
clinic
research
enterpris
nih
fund
fi
rst
clinic
translat
scienc
award
ctsa
academ
center
conduct
project
translat
research
ncrr
addit
center
name
subsequ
year
fda
play
key
regulatori
role
medic
practic
promot
translat
medicin
fda
critic
path
initi
subtitl
stagnat
innov
identifi
ed
key
area
develop
better
evalu
tool
biomark
diseas
model
streamlin
clinic
trial
har
bioinformat
move
manufactur
centuri
product
address
urgent
public
health
need
atrisk
popul
fda
earli
fda
releas
critic
path
opportun
list
outlin
scienc
project
bridg
translat
research
gap
fda
c
note
fi
rst
item
fda
opportun
list
diagnosticrel
area
refl
ect
import
diagnost
drive
innov
medic
practic
ratner
translat
diagnost
subfi
eld
translat
medicin
concern
diagnost
method
inform
given
import
diagnost
crucial
look
translat
issu
affect
area
innov
intent
close
gap
basic
research
medic
system
role
diagnost
continu
evolv
examin
translat
diagnost
view
largest
provid
labbas
test
nation
refer
laboratori
import
refer
lab
translat
everyth
home
brew
technolog
also
call
laboratorydevelop
test
licens
directli
academ
institut
fdaapprov
kit
purchas
manufactur
sophist
vitro
diagnost
multivari
index
assay
ivdmia
use
gener
patient
specifi
c
risk
data
fda
provid
complex
data
analysi
laboratori
test
educ
physician
patient
way
spearhead
uptak
new
diagnost
technolog
mind
chapter
focu
translat
diagnost
context
genom
person
medicin
practic
lesson
learn
bring
innov
diagnost
market
larger
refer
laboratori
larg
nation
lab
unit
state
includ
quest
diagnost
laboratori
corpor
america
hold
sonic
healthcar
genzym
mayo
clinic
associ
region
univers
patholog
arup
other
provid
lab
test
deliv
countri
complet
sever
million
assay
day
support
patient
care
understand
translat
diagnost
practic
nation
refer
laboratori
shed
light
challeng
success
bridg
translat
diagnost
gap
bench
bedsid
potenti
translat
diagnost
cancer
infecti
diseas
health
care
sector
also
discuss
goal
translat
diagnost
provid
improv
diagnost
procedur
lead
effi
caciou
therapi
improv
medic
outcom
earli
laboratori
medicin
consist
primarili
direct
examin
tissu
analysi
simpl
analyt
blood
molecular
biolog
techniqu
posit
dna
clone
dna
sequenc
nucleic
acid
hybrid
assay
led
earli
molecular
diagnost
southern
blot
hybrid
assay
use
detect
gene
delet
duchenn
muscular
dystrophi
repeat
expans
fragil
x
syndrom
gene
rearrang
diagnost
band
tcell
lymphoma
tsongali
silverman
fi
rst
molecular
diagnost
product
reach
market
includ
test
detect
viral
rna
dna
genet
test
singl
gene
diseas
test
determin
risk
develop
certain
cancer
breast
colon
cancer
mani
new
diagnost
technolog
enter
clinic
laboratori
part
evolut
nucleic
acid
amplifi
cation
technolog
use
amplifi
identifi
sequenc
target
singl
gene
sequenc
toward
system
biolog
approach
look
express
multipl
gene
respons
varieti
stimuli
condit
infecti
diseas
drug
therapi
cancer
bill
brown
system
biolog
often
use
synonym
function
genom
descript
genom
epigenom
infl
uenc
trait
interact
environment
variant
see
chapter
understand
translat
diagnost
gap
current
exist
movement
knowledg
necessari
understand
technolog
innov
potenti
applic
come
forth
tabl
microarray
technolog
typic
involv
tether
numer
probe
solid
substrat
dna
microarray
probe
usual
consist
small
oligonucleotid
complementari
dna
cdna
dna
target
commonli
form
fl
uoresc
label
cdna
genom
dna
fragment
hybrid
probe
detect
fl
uoresc
signal
directli
label
nucleic
acid
protein
sampl
common
microarray
detect
method
tefferi
et
al
dna
microarray
technolog
provid
data
dna
sequenc
variat
mutat
polymorph
gene
express
level
see
chapter
gene
express
profi
le
identifi
upregul
downregul
gene
target
novel
therapeut
cdna
array
also
use
classifi
patholog
subgroup
specifi
c
disord
polymorph
identifi
ed
genom
dna
target
probe
oligonucleotid
defi
ne
allel
differ
recent
advanc
microarray
technolog
involv
use
liquidphas
microparticlebas
array
one
exampl
would
beadbas
multiplex
allow
multipl
analyt
assay
well
molecular
diagnost
applic
microarray
technolog
includ
cancer
diagnosi
type
prognosi
infecti
diseas
identifi
cation
biodefens
applic
pharmacogenom
petrik
anoth
applic
array
technolog
array
compar
genom
hybrid
power
techniqu
detect
highlevel
amplifi
cation
homozyg
delet
small
genom
region
array
technolog
use
detect
highresolut
copi
number
chang
breast
renal
bladder
cancer
gabriel
et
al
petrik
use
genom
clone
sequenc
data
techniqu
lead
quickli
identifi
cation
clone
gene
associ
diseas
use
diagnost
target
therapeut
array
technolog
promis
revolution
fi
eld
medic
cytogenet
provid
molecular
karyotyp
without
need
cultur
cell
stain
chromosom
visual
see
chapter
proteom
seek
understand
structur
function
express
protein
encod
given
genom
see
chapter
human
genom
project
identifi
ed
approxim
human
gene
howev
estim
number
protein
product
time
higher
due
altern
splice
posttransl
modifi
cation
gene
product
petrik
proteom
also
encompass
protein
express
profi
le
function
age
state
environ
basic
techniqu
proteom
separ
protein
biolog
sampl
variou
separ
technolog
page
liquid
chromatographi
affi
niti
captur
follow
detect
protein
peptid
fragment
technolog
peptid
fi
ngerprint
mass
spectrometri
protein
array
antibodi
array
rice
et
al
proteom
analysi
base
mass
spectrometri
may
better
suit
identifi
cation
use
protein
biomark
technolog
autom
chip
technolog
use
protein
array
may
higher
clinic
diagnost
util
protein
array
use
protein
probe
solut
retain
abil
interact
specifi
calli
protein
molecul
protein
array
use
identifi
proteinprotein
interact
enzymesubstr
interact
antibodyantigen
interact
glycosyl
critic
import
posttransl
modifi
cation
cellular
protein
glycan
moieti
involv
wide
varieti
intracellular
cellcel
cellmatrix
recognit
event
glycom
studi
glycan
produc
human
role
protein
function
health
diseas
morrel
michalski
earli
technolog
use
separ
methodolog
mass
spectrometri
analys
similar
proteom
method
new
approach
develop
clinic
applic
includ
technolog
microcapillari
chromatographi
lectin
affi
niti
chromatographi
carbohydr
microarray
mass
spectrometri
miyamoto
glycan
analysi
contribut
drug
discoveri
clinic
assay
basic
research
underli
biolog
cancer
howev
greatest
promis
enhanc
genom
proteom
analysi
clinic
sampl
determin
effect
genet
environment
lifestyl
nutrit
state
patient
health
statu
epigenet
involv
studi
herit
chang
gene
function
occur
without
chang
dna
sequenc
see
chapter
epigenet
mechan
includ
dna
methyl
histon
acetyl
rna
interfer
see
chapter
neuropsychiatr
rheumatolog
diseas
cancer
may
affect
genotyp
epigenotyp
small
interf
rna
sirna
induc
specifi
c
posttranscript
gene
silenc
mammalian
system
hold
great
promis
therapeut
agent
diagnost
assay
develop
analyz
effect
new
therapi
cancer
cell
known
undergo
chang
distribut
includ
hypomethyl
hypermethyl
promot
cpg
island
associ
tumorsuppressor
gene
estel
integr
analysi
epigenet
state
cancer
cell
involv
dna
methyl
transcript
factor
bind
analysi
histon
acetyl
analysi
treatment
evalu
includ
histon
deacetylas
inhibitor
dna
methyltransferas
inhibitor
dna
methyl
pattern
develop
diagnost
biomark
detect
risk
assess
laird
see
chapter
biolog
imag
begun
play
increasingli
import
role
earli
detect
stage
diseas
see
chapter
recent
advanc
imag
includ
multislic
comput
tomographi
ct
wholebodi
magnet
reson
imag
mri
provid
earlier
detect
accur
determin
extent
diseas
schwaiger
peschel
tracer
techniqu
combin
positron
emiss
tomographi
pet
aid
discrimin
normal
tumor
tissu
molecular
imag
technolog
seek
visual
biolog
process
molecular
bind
site
new
advanc
petct
provid
qualit
quantit
assess
tumor
tissu
taken
togeth
molecular
diagnost
method
biolog
imag
aid
diseas
detect
predict
therapeut
effi
caci
provid
marker
diseas
treatment
near
futur
nanobiosens
envis
merger
molecular
diagnost
technolog
nanotechnolog
produc
nanobiosensor
capabl
detect
biolog
process
molecular
level
continu
oper
real
time
see
chapter
demidov
molecular
beacon
compris
nucleic
acid
probe
selfreport
optic
transduc
capabl
provid
feedback
monitor
therapeut
intervent
period
checkup
nanoparticlebas
molecular
detect
use
current
develop
multiplex
molecular
recognit
array
label
free
way
quantifi
specifi
c
bind
event
ming
cheng
cheng
et
al
quantum
dot
nanocryst
provid
nearli
unlimit
rang
sharpli
defi
ned
color
indic
tag
biomolecul
interest
provid
longliv
sensit
probe
nanodevic
use
microfl
uidic
technolog
may
produc
use
cancer
infecti
diseas
test
technolog
aid
continu
miniatur
molecular
diagnost
platform
necessari
evolut
molecular
diagnost
expand
point
care
use
system
biolog
approach
requir
simultan
detect
specifi
c
biolog
process
associ
diseas
factor
affect
diseas
progress
therapi
manag
infecti
diseas
associ
viral
bacteri
fungal
parasit
pathogen
includ
rapid
detect
identifi
cation
quantifi
pathogen
burden
pathogen
genotyp
nih
human
immunodefi
cienci
viru
hiv
quantifi
viral
load
wide
varieti
viral
pathogen
need
monitor
progress
diseas
respons
therapi
pathogen
genotyp
also
essenti
order
identifi
variant
resist
therapi
differenti
closelyrel
speci
viral
type
current
gold
standard
pathogen
detect
growth
pathogen
cultur
process
timeconsum
mani
case
noninform
diagnost
method
viral
detect
consist
primarili
immunolog
identifi
cation
antibodi
produc
respons
viral
infect
molecular
diagnost
util
nucleic
acid
amplifi
cation
test
naat
use
viral
load
monitor
genotyp
hiv
screen
hepat
b
c
hbv
hcv
west
nile
viru
wnv
paxton
hiv
hcv
window
infect
detect
antibodi
product
immunolog
method
fail
detect
viral
infect
import
issu
blood
safeti
identifi
cation
acut
infect
may
account
high
percentag
new
clinic
case
naat
test
implement
blood
screen
estim
prevent
fi
hcv
infect
per
year
anoth
advantag
naat
test
lie
fl
exibl
platform
face
emerg
infecti
diseas
threat
wnv
becam
public
health
concern
platform
convert
detect
monitor
wnv
within
month
incorpor
dna
microarray
technolog
rapid
pathogen
detect
genotyp
may
accomplish
simultan
recent
protein
microarray
coronavirus
includ
sever
acut
respiratori
syndrom
sar
viru
test
found
distinguish
sar
corona
virus
zhu
et
al
lowdens
microarray
test
research
use
subtyp
infl
uenza
avian
type
type
array
may
soon
clinic
util
monitor
infl
uenza
worldwid
develop
vaccin
eventu
point
care
applic
mehlmann
et
al
last
applic
import
determin
presenc
infl
uenza
sole
clinic
ground
diffi
cult
due
poor
specifi
citi
sensit
clinic
fi
nding
pathogen
caus
similar
symptom
infl
uenza
subtyp
caus
differ
symptom
exampl
patient
infl
uenza
symptom
infect
infl
uenza
viru
due
coronavirus
montalto
brown
combimatrix
develop
dna
microarray
detect
type
infl
uenza
strain
tm
bioscienc
corp
luminex
develop
major
human
respiratori
viru
array
molecular
diagnost
util
sexual
transmit
diseas
chlamydia
trachom
nisseria
gonorrhea
well
bacteri
pathogen
legionella
pneumophilia
legionnair
diseas
borrelia
burgdoreri
lyme
diseas
mycobacterium
tuberculosi
bordetella
pertussi
b
parapertussi
whoop
cough
despit
effect
vaccin
program
bordetella
pertussi
remain
import
highli
contagi
diseas
due
fact
newborn
appear
gain
passiv
matern
protect
vaccineinduc
immun
far
less
complet
expect
realtim
pcr
assay
accur
detect
differenti
dna
agent
pertussi
syndrom
develop
vincart
et
al
realtim
pcr
assay
provid
result
within
h
sampl
receipt
provid
clinician
time
accur
inform
provid
cultur
direct
fl
uoresc
antibodi
serolog
test
even
convent
pcr
method
addit
applic
includ
tissu
product
test
bioterror
monitor
character
hostpathogen
interact
search
addit
diagnost
biomark
standard
diagnost
procedur
human
tumor
use
combin
histopatholog
special
stain
immunohistolog
radiolog
clinic
data
diagnost
deriv
manner
provid
data
tissu
origin
tumor
type
stage
grade
along
inform
complet
surgic
tumor
remov
dietel
ser
howev
test
neither
sensit
specifi
c
enough
differenti
patient
respond
treatment
applic
highthroughput
dna
array
technolog
provid
gene
express
profi
le
revolution
tumor
diagnost
led
identifi
cation
novel
tumor
subgroup
otherwis
indistinguish
tumor
dietel
ser
research
also
identifi
ed
gene
express
use
predict
metastat
potenti
breast
carcinoma
futur
technolog
take
system
approach
need
identifi
patient
benefi
novel
therapi
method
must
capabl
detect
multipl
oncogen
pathway
tumor
therapi
must
adapt
routin
clinic
diagnost
test
possibl
method
includ
tissu
microarray
forwardphas
protein
microarray
capabl
simultan
detect
multipl
protein
interact
singl
sampl
reversephas
protein
microarray
capabl
probe
multipl
analyt
specifi
c
antibodi
gulmann
et
al
test
modal
may
appli
primari
metastat
tumor
biopsi
blood
biopsi
rare
circul
tumor
cell
understand
role
human
genet
variat
diseas
suscept
select
effi
caci
therapeut
essenti
compon
optim
care
pharmacogenom
look
impact
patient
genet
variat
respons
therapeut
see
chapter
pharmacogenom
also
infl
uenc
deliveri
cost
healthcar
phillip
et
al
sensit
toxic
resist
medic
standard
dose
prime
exampl
effect
genotyp
heterogen
within
patient
popul
well
known
clinic
relev
exampl
includ
differenti
respons
warfarin
codein
thiopurin
antileukem
drug
succinylcholin
genet
differ
receptor
structur
affi
niti
drug
metabol
drug
transport
system
known
play
import
role
differenti
respons
drug
therapi
advers
drug
reaction
adr
advers
drug
reaction
result
hospit
mortal
montgomeri
louie
gene
associ
adr
encod
receptor
metabol
enzym
metabolit
transport
protein
gene
implic
environment
toxin
suscept
cancer
predisposit
drug
effi
caci
directli
relat
bind
drug
molecul
cell
surfac
receptor
exampl
demonstr
patient
express
high
level
betaadrenerg
receptor
respons
betaagonist
antagonist
convers
express
low
level
receptor
requir
higherdrug
level
achiev
compar
pharmacolog
effect
insid
cell
drug
metabol
number
enzym
catalyz
alter
molecular
structur
therapeut
drug
genet
variat
gene
encod
metabol
enzym
lead
differ
enzym
activ
character
extens
standard
dosag
intermedi
slower
extens
alter
dosag
poor
enzym
defici
treat
drug
ultrarapid
break
drug
faster
extens
effect
reduc
effect
drug
therapi
one
class
metabol
enzym
cytochrom
superfamili
cyp
compris
isozym
enzym
metabol
larg
number
drug
small
molecul
mutagen
carcinogen
modifi
parent
molecul
function
group
polymorph
gene
result
homozyg
recess
inact
genotyp
convert
codein
activ
metabolit
morphin
rabinowitz
poljak
fdaapprov
roch
diagnost
amplichip
test
molecular
array
detect
mutat
gene
contribut
metabol
quarter
prescrib
drug
data
provid
amplichip
aid
physician
determin
drug
select
dosag
exampl
potenti
impact
type
illustr
drug
warfarin
metabol
enzym
encod
gene
polymorph
gene
infl
uenc
warfarin
dose
requir
warfarinassoci
bleed
wittkowski
demonstr
mainten
warfarin
dose
estim
demograph
clinic
pharmacogenet
factor
gage
et
al
second
gene
associ
averag
weekli
warfarin
dose
requir
maintain
patient
desir
anticoagul
target
inform
expect
predict
model
warfarin
dose
develop
help
one
million
patient
year
take
warfarin
appropri
dosag
avoid
thromboembol
event
li
et
al
twelv
percent
user
current
experi
major
bleed
episod
death
result
mani
abacavir
nucleosid
analog
potent
inhibitor
hiv
revers
transcriptas
enzym
howev
patient
develop
hypersensit
reaction
result
life
threaten
hypotens
possess
human
leukocyt
antigen
hla
b
risk
factor
abacavir
hypersensit
use
hlab
genotyp
screen
shown
effect
reduc
incid
abacavir
hypersensit
exclus
patient
posit
allel
abacavir
combin
treatment
mallal
et
al
adopt
pharmacogenom
test
impact
drug
safeti
issu
demonstr
costeffect
hugh
et
al
addit
associ
specifi
c
hla
genotyp
life
threaten
adr
includ
allopurinol
hlab
hung
et
al
carbamazeprin
hlab
dainichi
et
al
decemb
fda
releas
guidelin
call
genet
test
hlab
genotyp
prior
start
carbamazeprin
therapi
patient
asian
ancestri
fda
cancer
pharmacogenom
impact
patient
safeti
therapeut
effi
caci
use
select
treatment
choic
base
tumor
genom
patient
genotyp
methodolog
molecular
cytogenet
somat
mutat
detect
gene
express
profi
ling
use
examin
genotyp
differ
cancer
tissu
patient
respons
therapi
chronic
myelogen
leukemia
cml
one
common
form
leukemia
case
cml
result
chromosom
abnorm
wherebi
dna
chromosom
contain
protooncogen
cabl
transloc
onto
chromosom
within
breakpoint
cluster
region
bcr
gene
bill
brown
result
gene
fusion
constitut
express
protein
tyrosin
kinas
activ
activ
affect
intracellular
signal
pathway
result
unregul
cell
prolifer
molecular
diagnosi
cml
util
quantit
pcr
fluoresc
situ
hybrid
fish
also
use
visual
transloc
chromosom
oral
drug
imatinib
gleevec
specifi
calli
design
select
inhibitor
bcrabl
tyrosin
kinas
demonstr
therapeut
superior
convent
drug
therapi
molecular
diagnost
test
use
monitor
respons
gleevec
develop
therapeut
resist
hereditari
nonpolyposi
colorect
cancer
hnpcc
common
hereditari
caus
colon
cancer
account
colon
cancer
case
see
chapter
caus
mutat
least
fi
dna
mismatch
repair
gene
dna
test
avail
common
gene
hnpcc
syndrom
predispos
person
develop
colon
cancer
young
age
presymptomat
predisposit
test
famili
conduct
sinc
approxim
tumor
hnpcc
patient
show
microsatellit
instabl
test
phenomenon
alon
good
guid
necess
molecular
character
gene
sequenc
use
identifi
precis
mutat
mutat
data
along
dna
microsatellit
instabl
test
result
use
identifi
fi
rstdegre
rel
hnpcc
hnpcc
implic
clinic
data
immunohistochemistri
test
conduct
tumor
tissu
confi
rmation
diagnosi
way
member
famili
hnpcc
mean
know
need
aggress
monitor
treatment
thiopurin
thioguanin
mercaptopurin
commonli
use
anticanc
therapeut
thiopurin
methyltransferas
tpmt
enzym
catalys
methyl
thiopurin
tpmt
gene
polymorph
one
patient
defi
cient
enzym
activ
standard
dose
lead
toxic
accumul
thiopurin
fatal
three
mutat
account
major
mutant
allel
genet
test
avail
children
leukemia
receiv
medic
routin
screen
defi
cienci
gene
bill
brown
late
fdaapprov
third
wave
technolog
invad
molecular
assay
use
identifi
patient
could
experi
advers
reaction
camptosar
irinotecan
colorect
chemotherapi
drug
grebow
test
detect
mutat
gene
produc
metabol
enzym
activ
therapeut
one
fi
rst
pharmacogonom
test
fda
approv
use
companion
diagnost
specifi
c
drug
final
genet
test
predict
futur
diseas
risk
base
inherit
germlin
mutat
also
avail
mutat
associ
higher
risk
breast
ovarian
cancer
approxim
women
develop
breast
cancer
brca
test
brac
analysi
test
expens
provid
inform
limit
therapeut
respons
test
experi
initi
resist
among
insur
provid
reimburs
phillip
et
al
factor
infl
uenc
uptak
pharmacogenom
diagnost
test
clinic
valid
util
need
demonstr
commun
physician
patient
rapid
reliabl
inexpens
easili
interpret
molecular
test
increas
clinic
use
diagnost
test
shah
clinic
relev
must
also
demonstr
may
limit
use
technolog
applic
exist
choic
treatment
addit
due
screen
natur
test
costeffect
must
demonstr
flower
veenstra
howev
determin
costeffect
genet
technolog
simpl
fact
led
opposit
larg
scale
uptak
healthcar
rogowski
addit
obstacl
deploy
pharmacogenom
test
includ
obtain
reason
reimburs
test
educ
physician
patient
valu
test
interpret
result
investig
specifi
c
exampl
translat
diagnost
reveal
crucial
issu
challeng
face
new
method
enter
health
care
prior
therapeut
truli
impact
cours
viral
diseas
avail
symptom
could
affect
antibiot
equival
treat
viral
diseas
howev
pharmaceut
compani
number
antivir
compound
specifi
calli
tailor
hiv
well
clinic
trial
need
accur
biomark
analyz
effect
new
therapi
converg
therapeut
diagnost
would
lead
birth
theranost
diagnost
test
link
applic
specifi
c
therapi
warner
roch
diagnost
began
roch
access
program
provid
two
free
baselin
hiv
viral
load
test
anyon
unit
state
hiv
jame
refer
laboratori
help
execut
program
began
success
uptak
hiv
viral
load
test
marketplac
tradit
diagnost
molecular
diagnost
test
need
demonstr
util
perform
adopt
practic
first
must
unmet
clinic
need
clearli
case
hiv
secondli
develop
antivir
therapi
hiv
viral
load
test
provid
inform
result
therapeut
action
also
provid
mean
continu
monitor
effi
caci
treatment
without
therapeut
test
would
provid
inform
would
inform
treatment
hiv
addit
factor
sped
uptak
hiv
viral
load
test
initi
test
involv
rel
small
group
highli
focus
clinician
made
much
simpler
educ
physician
use
viral
load
test
manag
hiv
highli
motiv
patient
fuel
demand
test
viral
load
test
signifi
cant
role
earli
clinic
trial
antivir
therapeut
becam
object
measur
tool
even
proteas
inhibitor
approv
physician
use
public
antivir
therapeut
includ
hiv
viral
load
result
thought
leader
particip
trial
becam
earli
adopt
test
even
test
fda
approv
viral
load
test
put
kit
format
becam
fda
approv
approxim
time
fi
rst
proteas
inhibitor
becam
avail
recommend
viral
load
test
becam
part
standard
guidelin
treat
hiv
infect
chesebro
everett
theranost
becam
tie
use
drug
roch
amplicor
access
program
led
rapid
test
util
volum
increas
manufactur
develop
autom
hiv
manag
requir
rel
frequent
monitor
often
four
time
per
year
therefor
test
one
test
constitut
genet
test
hiv
viral
load
test
also
obtain
cpt
code
facilit
reimburs
addit
kit
manufactur
nation
refer
lab
patient
doctor
work
ensur
test
reimburs
factor
help
make
hiv
viral
load
test
cost
effect
foundat
hiv
prevent
effort
combin
viral
load
test
new
therapeut
transform
hiv
uniformli
fatal
diseas
chronic
treatabl
diseas
therefor
hiv
becom
diseas
action
result
recent
center
diseas
control
cdc
recommend
call
gener
popul
screen
hiv
statu
exampl
translat
diagnost
patient
care
success
mani
hallmark
success
diagnost
test
place
unmet
clinic
need
action
result
obtain
test
test
ultim
cost
effect
highthroughput
analysi
becam
avail
reimburs
issu
rapidli
resolv
similar
converg
hiv
therapeut
need
hiv
viral
load
assay
develop
anticanc
therapeut
herceptin
requir
clinic
laboratori
test
determin
receptor
statu
tsongali
silverman
amplifi
cation
human
epiderm
growth
factor
receptor
gene
primari
breast
cancer
carcinoma
shown
correl
poor
clinic
prognosi
breast
cancer
patient
ferretti
et
al
oncogen
activ
breast
cancer
overexpress
protein
cell
surfac
found
stimul
uncontrol
tumor
growth
herceptin
trastuzumab
recombin
dnaderiv
monoclon
antibodi
bind
high
affi
niti
specifi
citi
extracellular
domain
receptor
inhibit
prolifer
overexpress
tumor
cell
herceptin
alon
associ
object
respons
extens
pretreat
patient
metastat
breast
cancer
overexpress
previous
untreat
patient
mckeag
perri
cardiac
dysfunct
occur
patient
receiv
herceptin
paclitaxel
patient
receiv
herceptin
given
high
cost
herceptin
therapi
signifi
cant
side
effect
herceptin
treatment
patient
target
natur
therapeut
necessari
restrict
therapi
patient
expect
respond
treatment
fda
approv
herceptin
herceptest
treatment
metastat
breast
cancer
protein
detect
primarili
ihc
fish
method
herceptest
pathvys
fish
assay
amplifi
cation
use
select
patient
herceptin
therapi
uptak
diagnost
test
receptor
statu
greatli
acceler
due
safeti
issu
associ
therapi
addit
assay
requir
new
tissu
sampl
mani
case
archiv
sampl
paraffi
n
block
alreadi
sent
refer
lab
estrogen
progesteron
analysi
physician
could
mere
check
anoth
box
test
order
sheet
random
clinic
trial
recent
demonstr
signifi
cant
differ
surviv
compar
chemotherapi
chemotherapi
plu
herceptin
women
overexpress
breast
cancer
either
metastat
adjuv
set
ferretti
et
al
thu
prognost
poor
outcom
patient
becom
predict
marker
respons
therapi
unfortun
lack
concord
among
detect
techniqu
differ
score
system
use
determin
statu
lack
lab
standard
qualiti
base
test
experi
led
signifi
cant
variat
test
nelson
recent
capasco
guidelin
includ
test
algorithm
qa
requir
lab
evalu
score
system
help
address
issu
capasco
human
papillomaviru
hpv
major
caus
cervic
cancer
diseas
kill
women
worldwid
year
gottlieb
unit
state
million
new
case
report
annual
least
million
peopl
countri
alreadi
infect
niaid
approxim
type
hpv
viru
sexual
transmit
rare
caus
symptom
diseas
type
lowcanc
risk
type
caus
genit
wart
lowand
highrisk
type
caus
growth
abnorm
cell
detect
pap
test
done
gynecolog
exam
bethesda
system
divid
common
clearli
abnorm
pap
result
either
lowgrad
squamou
intraepitheli
lesion
lsil
mild
cell
chang
associ
hpv
highgrad
squamou
intraepitheli
lesion
hsil
precancer
cell
chang
treat
physician
cancer
clinician
manag
notcompletelynorm
pap
result
known
ascu
atyp
squamou
cell
undetermin
signifi
canc
may
benefi
addit
inform
provid
hpv
test
fdaapprov
digen
corpor
highrisk
hpv
dna
test
use
women
abnorm
pap
test
result
fda
expand
use
hpv
test
conjunct
pap
test
routin
screen
test
use
hybrid
captur
technolog
directli
detect
hpv
viru
dna
current
system
allow
highthroughput
test
woman
fi
tting
appropri
clinic
criteria
neg
pap
neg
hpv
dna
test
less
one
one
thousand
chanc
develop
cervic
cancer
fdaapprov
merck
co
gardisil
recombin
vaccin
design
prevent
major
hpvrelat
clinic
diseas
caus
hpv
hpv
type
account
approxim
case
cervic
cancer
hpv
caus
approxim
genit
wart
case
clinic
studi
gardasil
prevent
hpv
cervic
cancer
women
previous
expos
relev
hpv
type
studi
conduct
women
age
vaccin
nearli
effect
prevent
precancer
lesion
genit
wart
gardisil
evalu
approv
month
fda
prioriti
review
process
process
product
potenti
provid
signifi
cant
health
benefi
ts
fda
june
cdc
advisori
committe
immun
practic
acip
recommend
femal
age
receiv
hpv
vaccin
part
routin
primari
care
hpv
diagnost
test
expand
util
test
limit
abnorm
pap
test
result
diagnost
test
conjunct
pap
test
standard
care
routin
screen
women
year
age
older
move
liquid
pap
test
previous
common
smear
method
remov
need
addit
sampl
hpv
test
develop
effect
vaccin
bolster
public
awar
hpv
technolog
innov
reduc
sampl
barrier
improv
therapeut
option
along
factor
aid
rapid
uptak
hpv
test
diagnost
test
develop
rapid
rate
technolog
diagnost
test
expand
howev
diagnost
test
fi
nd
way
applic
health
care
clinic
util
may
demonstr
due
lack
action
result
costeffect
highthroughput
method
adequ
reimburs
exampl
earli
asymptomat
glaucoma
test
wide
abandon
earli
detect
affect
outcom
test
may
achiev
analyt
perform
characterist
requir
good
diagnost
assay
sensit
specifi
citi
predict
valu
must
high
gaeta
reproduc
precis
clinic
report
rang
must
demonstr
irwig
et
al
exampl
microarray
technolog
translat
wide
diagnost
applic
problem
sensit
reproduc
solv
petrik
rigor
evalu
diagnost
test
prior
introduct
clinic
practic
goal
standard
report
diagnost
accuraci
stard
initi
bossuyt
et
al
evalu
genom
applic
practic
prevent
egapp
cdc
project
establish
evidencebas
process
assess
applic
genom
technolog
cdc
nation
offi
ce
public
health
genom
ultim
role
diagnost
clinic
care
must
balanc
tool
avail
physician
patient
histori
physic
exam
halkin
et
al
addit
technolog
advanc
must
produc
increas
effi
caci
treatment
excess
produc
improv
deliveri
older
treatment
woolf
johnson
futur
innov
diagnost
hold
great
promis
provid
rapid
identifi
cation
diseas
suscept
statu
monitor
diseas
progress
therapeut
effi
caci
reduc
adr
speed
appropri
therapi
select
develop
person
medicin
optim
diseas
prevent
cure
see
promis
unfold
number
challeng
must
overcom
diagnost
test
must
address
unmet
medic
need
lead
action
event
demonstr
clinic
util
diagnost
must
also
demonstr
high
specifi
citi
sensit
predict
valu
novel
diagnost
ultim
translat
effect
addit
obstacl
must
also
overcom
diagnost
test
must
prove
function
health
care
set
exampl
new
sampl
type
need
procur
diagnost
test
replac
add
exist
assay
retain
current
sampl
procedur
clinic
valu
test
clearli
demonstr
thought
leader
earli
adopt
patient
advocaci
group
stakehold
requir
rapid
uptak
diagnost
role
profession
societi
guidelin
cm
coverag
technolog
review
insur
industri
regul
must
consid
reimburs
issu
delay
uptak
access
test
larg
sector
patient
popul
patient
safeti
issu
within
specifi
c
treatment
warrant
rapid
clinic
uptak
train
requir
clinic
lab
select
appropri
technolog
pool
technic
approach
diagnost
problem
best
way
deliv
diagnost
healthcar
provid
user
new
diagnost
test
best
use
optim
healthcar
benefi
stand
alon
diagnost
link
treatment
protocol
companion
diagnost
theranost
final
new
accur
reliabl
diagnost
method
make
bias
inaccuraci
character
practic
clinic
medicin
patient
report
thing
past
lost
gain
crucial
concern
challeng
must
address
virtual
new
diagnost
reach
full
potenti
improv
health
care
close
translat
gap
highlight
issu
other
requir
research
knowledg
translat
fi
nancial
support
awar
lesson
learn
previous
translat
diagnost
tabl
even
though
diagnost
infl
uenc
healthcar
decisionmak
make
less
hospit
cost
medicar
cost
nordhoff
next
decad
new
diagnost
predict
even
greater
impact
healthcar
decis
make
provid
improv
diseas
predict
prognost
therapi
guidanc
studi
found
reduct
direct
hospit
outpati
charg
chang
patient
health
statu
accur
monitor
yet
diagnost
test
recommend
standard
care
underus
time
olsen
low
complianc
diagnosticsbas
qualiti
measur
diabet
cardiovascular
diseas
colorect
cancer
breast
cancer
link
avoid
death
million
avoid
healthcar
cost
olsen
effi
cient
translat
new
knowledg
technolog
critic
promis
innov
diagnost
person
medicin
realiz
improv
translat
innov
diagnost
requir
understand
specifi
c
lesson
learn
previou
translat
also
understand
conceptu
framework
within
diagnost
translat
occur
tabl
